Close

After-Hours Stock Movers 05/18: (LPTH) (PRPL) (TTWO) Higher; (IOVA) (QUIK) (LAD) Lower (more...)

Go back to After-Hours Stock Movers 05/18: (LPTH) (PRPL) (TTWO) Higher; (IOVA) (QUIK) (LAD) Lower (more...)

Lithia Motors (LAD) Prices 3.1M Share Common Offering at $322/Sh

May 20, 2021 5:50 AM EDT

Lithia Motors & Driveway (NYSE: LAD) today announced the pricing of its public offering (the "Offering") of 3,105,590 shares of its Class A common stock (the "common stock") at a price to the public of $322.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 465,838 shares of common stock at the same public offering price, less underwriting discounts and commissions. The offering is expected to close on May 24, 2021, subject to the satisfaction of customary closing conditions.

In addition, today Lithia concurrently announced the pricing of its private... More

Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho

May 19, 2021 12:42 PM EDT

Mizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.

"The commercial potential for lifileucel remains but the question... More

Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA Push

May 19, 2021 8:05 AM EDT

Stifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a Buy rating.

The analyst commented, "Although yesterday's update has us scratching our heads and leaves us with a number of outstanding questions, we remain... More

Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay

May 19, 2021 7:58 AM EDT

Chardan Capital Markets analyst Geulah Livshits lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $51.00 (from $54.00) while maintaining a Buy rating.

The analyst commented, "Yesterday, after market close, Iovance Biotherapeutics announced revised guidance for BLA filing on tumor infiltrating lymphocyte (TIL)... More

Purple Innovation (PRPL) Prices 7.308M Shares Secondary Offering at $30/Sh

May 19, 2021 5:48 AM EDT

Purple Innovation, Inc. (NASDAQ: PRPL), a leader in comfort innovation and the creator of the renowned Purple® Mattress, today announced the pricing of an underwritten secondary public offering of 7,308,792 shares of its Class A common stock to be sold by Coliseum Capital Partners, L.P., Coliseum Co-Invest Debt Fund, L.P., Blackwell Partners LLC Series A, and Coliseum Capital Co-Invest III, L.P. (collectively, the "Selling Stockholders"). The shares of Class A common stock are being sold at a price of... More

Roth Capital Upgrades QuickLogic (QUIK) to Buy

May 19, 2021 3:31 AM EDT

Roth Capital analyst Seju Desilva upgraded QuickLogic (NASDAQ: QUIK) from Neutral to Buy with a price target of $8.00 (from $7.00).

The analyst comments "We believe QUIK rpresents a differentiated investment opportunity in sensor processing and licensing capability. QUIK reported softer than expected results impacted by... More